Transanal versus laparoscopic total mesorectal excision for mid and low rectal cancer (Ta-LaTME study): multicentre, randomized, open-label trial

Keyphrases

• Transanal 100%
• Transanal Total Mesorectal Excision (taTME) 100%
• Open-label Trial 100%
• Low Rectal Cancer 100%
• Conversion to Open Surgery 16%
• Oncological Outcomes 11%
• Local Recurrence 11%
• Postoperative Morbidity 11%
• Modified Intention-to-treat 11%
• Postoperative Recovery 11%
• Resection 5%
• Pathological Outcomes 5%
• Anastomosis 5%
• No Significant Difference 5%
• Group Differences 5%
• Surgeons 5%
• Per-protocol Analysis 5%
• Intraoperative Complications 5%
• Intention-to-treat Analysis 5%
• Morbidity Mortality 5%
• Conversion Rate 5%
• Open Surgery 5%
• Intracorporeal 5%
• Anastomotic Leakage 5%
• Rectal Adenocarcinoma 5%
• Minimally Invasive Surgical Procedures 5%
• Composite Outcome 5%
• Conversion Surgery 5%

Medicine and Dentistry

• Rectum Cancer 100%
• Total Mesorectal Excision 100%
• Open-Label Trial 100%
• Conversion to Open Surgery 16%
• Recurrent Disease 11%
• Intention-to-Treat Analysis 11%
• Postoperative Recovery 11%
• Surgical Anastomosis 5%
• Minimally Invasive Procedure 5%
• Peroperative Complication 5%
• Open Surgery 5%
• Anastomosis Leakage 5%
• Rectum Carcinoma 5%
• Surgeon 5%
• Surgery 5%